COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiaf523 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Quincy Hofsink und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Hematologic Neoplasms, COVID-19, COVID-19 Vaccines, Vaccine Efficacy. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Netherlands Organization for Health Research and Development, Amsterdam University Medical Centers, Dutch Ministry of Health.
Abstract (Originalsprache)
Background
In patients with hematologic malignancies, COVID-19 vaccine effectiveness is unknown and determinants of severe COVID-19 lack granularity.
Methods
To identify determinants of SARS-CoV-2 infection outcome we conducted a population-based, nationwide cohort study, including all adult Dutch residents who tested positive for SARS-CoV-2 between 1 June 2020, and 31 March 2022. Individuals were classified as having a (history of) hematologic malignancy, solid malignancy, or no malignancies. Primary outcome was severe COVID-19, defined as COVID-19-related hospitalization or death following first SARS-CoV-2 infection.
Results
Among 4 649 341 included individuals, those with hematologic malignancies were at highest risk of severe COVID-19. Vaccine effectiveness against severe COVID-19 in patients with hematologic malignancies was up to 74% (95% CI, 60% to 83%), depending on the SARS-CoV-2 variant period, the number of received vaccinations, and the time interval since vaccination. Risk of severe COVID-19 was highest for patients with recently diagnosed hematologic malignancies and declined over time, except for patients with chronic hematologic malignancies. Risk of severe COVID-19 tended to be higher in patients on tumor-specific treatment such as CD38 and CD20 antibodies, proteasome inhibitors, and protein kinase inhibitors.
Conclusions
COVID-19 vaccination lowered the risk of severe COVID-19 in SARS-CoV-2-infected patients with hematologic malignancies, although these patients remained at elevated risk compared with others. Determinants of severe COVID-19 included type of malignancy, time interval between malignancy diagnosis and SARS-CoV-2 infection, and treatment. These data can guide healthcare professionals in designing additional prevention and therapeutic strategies against respiratory virus infections for patients with hematologic malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
- Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam UMC, Amsterdam, The Netherlands.
- Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
- Department of Epidemiology and Data Science, Amsterdam UMC, VU University, Amsterdam, The Netherlands.
- Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
- Department of Hematopoiesis, Sanquin Research, Amsterdam, The Netherlands.
ORCID-Profile: Quincy Hofsink, Birgit I Lissenberg-Witte, Sabine Haggenburg, Abraham Goorhuis, Astrid A M van der Veldt, Nicolette F de Keizer, Avinash G Dinmohamed, Joyce Pijpers, Brechje de Gier, Jarom Heijmans
Förderung
- Netherlands Organization for Health Research and Development
- Amsterdam University Medical Centers
- Dutch Ministry of Health
- Welfare and Sports
- Netherlands Comprehensive Cancer Organization
- IKNL
Zitieren
APA
Hofsink, Q., Lissenberg-Witte, B. I., Haggenburg, S., Goorhuis, A., Hazenberg, M. D., Rutten, C. E., den Tex, P., de Vries, E. G. E., van der Veldt, A. A. M., Kemmeren, J. M., de Keizer, N. F., Huijgens, P. C., Dinmohamed, A. G., van Roon, A., Pijpers, J., van Roekel, C., van den Hof, S., Hahné, S. J. M., de Gier, B., …, & Nijhof, I. S. (2026). COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf523
Vancouver
Hofsink Q, Lissenberg-Witte BI, Haggenburg S, Goorhuis A, Hazenberg MD, Rutten CE, et al. COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiaf523
BibTeX
@article{Hofsink2026,
author = {Hofsink, Quincy and Lissenberg-Witte, Birgit I and Haggenburg, Sabine and Goorhuis, Abraham and Hazenberg, Mette D and Rutten, Caroline E and den Tex, Paul and de Vries, Elisabeth G E and van der Veldt, Astrid A M and Kemmeren, Jeanet M and de Keizer, Nicolette F and Huijgens, Peter C and Dinmohamed, Avinash G and van Roon, Annika and Pijpers, Joyce and van Roekel, Caren and van den Hof, Susan and Hahné, Susan J M and de Gier, Brechje and Heijmans, Jarom and Nijhof, Inger S},
title = {COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiaf523}
}
EUVIMED